These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30194623)

  • 1. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
    Bounthavong M; Butler J; Dolan CM; Dunn JD; Fisher KA; Oestreicher N; Pitt B; Hauptman PJ; Veenstra DL
    Pharmacoeconomics; 2018 Dec; 36(12):1463-1473. PubMed ID: 30194623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain.
    González-Juanatey JR; González-Franco Á; de Sequera P; Valls M; Ramirez de Arellano A; Pomares E; Nieves D
    J Med Econ; 2022; 25(1):640-649. PubMed ID: 35510569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.
    Widén J; Ivarsson M; Schalin L; Vrouchou P; Schwenkglenks M; Heimbürger O; Ademi Z; Sutherland CS
    Pharmacoeconomics; 2020 Jul; 38(7):747-764. PubMed ID: 32239480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK.
    Ramirez de Arellano A; Jakutis G; Hunt B
    J Med Econ; 2024; 27(1):1011-1017. PubMed ID: 39023516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.
    Piña IL; Yuan J; Ackourey G; Ventura H
    Prog Cardiovasc Dis; 2020; 63(5):656-661. PubMed ID: 33007353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
    de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
    Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
    Glick HA; Orzol SM; Tooley JF; Remme WJ; Sasayama S; Pitt B
    Cardiovasc Drugs Ther; 2002 Jan; 16(1):53-9. PubMed ID: 12085979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
    Ademi Z; Pasupathi K; Liew D
    Medicine (Baltimore); 2016 May; 95(18):e3531. PubMed ID: 27149456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
    Pitt B; Bakris GL; Weir MR; Freeman MW; Lainscak M; Mayo MR; Garza D; Zawadzki R; Berman L; Bushinsky DA
    ESC Heart Fail; 2018 Aug; 5(4):592-602. PubMed ID: 29767459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.
    Stawowczyk E; Ward T; Paoletti E; Senni M; de Arellano AR
    Cost Eff Resour Alloc; 2024 May; 22(1):42. PubMed ID: 38769560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
    J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients.
    Tian L; Fu S; Li M; Zhao X; Li H
    Front Public Health; 2023; 11():1196789. PubMed ID: 38145082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.
    Bakhai A; Palaka E; Linde C; Bennett H; Furuland H; Qin L; McEwan P; Evans M
    J Med Econ; 2018 Dec; 21(12):1172-1182. PubMed ID: 30160541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.